Semaglutide Liquid Placed on the Tongue for Adults With Obesity
Tests semaglutide given as a liquid on the tongue in adults with obesity.
Key facts
- Who runs it
- Gila Therapeutics, Inc.
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 40 people, planned
- Started
- 17 Jun 2026
- Expected to end
- May 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Semaglutide 6 mg liquid emulsion formulation
- Wegovy® (semaglutide) Tablet
- Placebo liquid emulsion formulation
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity (body mass index 30 to 45) to test semaglutide given as a liquid on the tongue.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Obesity with a body mass index of 30 to 45.
Main reasons for not taking part
- Type 2 diabetes mellitus
- Multiple Endocrine Neoplasia Type 2
- Medullary thyroid cancer
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Body Mass Index 30 to 45
Who cannot take part
- Type 2 Diabetes Mellitus
- Medullary thyroid cancer
- Multiple Endocrine Neoplasia Type 2
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Clinical Research Institute of MinnesotaMinneapolis, United StatesContact: Gary D Berman, M.D.Taking people
About the trial
What the trial wants to find out
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
The 3 groups in the trial
- Semaglutide liquid emulsion formulationTreatment being tested
Semaglutide 6 mg liquid emulsion formulation daily
Treatment: Semaglutide 6 mg liquid emulsion formulation
- Placebo liquid emulsion formulationPlacebo, for comparison
Placebo liquid emulsion formulation daily
- Wegovy TabletExisting treatment, for comparison
Wegovy (semaglutide) 25 mg Tablet daily after 90 day titration
Treatment: Wegovy® (semaglutide) Tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity
- Plain-language title
- Semaglutide Liquid Placed on the Tongue for Adults With ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07728383, who can take part
- Record updated
- 27 July 2026